Denali Therapeutics Inc.
DNLI
$14.80
$0.432.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 1.27M | 295.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 1.27M | 295.39M |
| Cost of Revenue | 227.53M | 228.73M | 244.65M | 236.15M | 236.97M |
| Gross Profit | -227.53M | -228.73M | -244.65M | -234.88M | 58.42M |
| SG&A Expenses | 109.56M | 105.44M | 100.15M | 100.52M | 101.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 515.21M | 501.88M | 512.50M | 504.38M | 511.43M |
| Operating Income | -515.21M | -501.88M | -512.50M | -503.11M | -216.04M |
| Income Before Tax | -453.87M | -422.71M | -427.46M | -419.62M | -137.22M |
| Income Tax Expenses | 68.00K | 68.00K | 30.00K | 30.00K | 30.00K |
| Earnings from Continuing Operations | -453.94 | -422.77 | -427.49 | -419.65 | -137.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -453.94M | -422.77M | -427.49M | -419.65M | -137.25M |
| EBIT | -515.21M | -501.88M | -512.50M | -503.11M | -216.04M |
| EBITDA | -508.40M | -495.23M | -503.95M | -494.61M | -207.20M |
| EPS Basic | -2.67 | -2.58 | -2.76 | -2.85 | -0.93 |
| Normalized Basic EPS | -1.71 | -1.74 | -1.92 | -1.98 | -0.78 |
| EPS Diluted | -2.67 | -2.58 | -2.77 | -2.86 | -0.97 |
| Normalized Diluted EPS | -1.71 | -1.74 | -1.92 | -1.98 | -0.80 |
| Average Basic Shares Outstanding | 679.60M | 657.78M | 625.94M | 594.13M | 562.34M |
| Average Diluted Shares Outstanding | 679.60M | 657.78M | 625.94M | 594.13M | 566.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |